Compare iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares S&P GSCI Commodity-Indexed Trust ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $32.6, while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| GSG | RXRX | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $34.77 | $6.79 |
52-Week Low | $22.06 | $2.84 |
Market Cap | — | $1.81B |
Enterprise Value | — | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSG trades at $32.65, up 1.02% today, with a bearish technical signal driven by moving averages. Recent news highlights its energy-centric commodity exposure, which fueled strong H1 2026 performance but faces volatility risks. Financial ratios are unavailable, limiting fundamental clarity.
Outlook is cautious due to sector volatility and geopolitical risks, with a recent downgrade to Hold. Opportunities lie in broad commodity exposure, but investors should weigh energy price swings and lack of current financial data against potential gains.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
